SAB BIO's SAB-142 Phase 1 trial data supports its safety and pharmacodynamic activity, paving the way for a Phase 2b trial in ...

European Patent Office (EPO) grants EU Patent No. EP3583125 B1 covering the Company’s Fully Human Albumin Binding (FHAB®) ...

Scientists from the National Institutes for Food and Drug Control have characterized antibody-drug conjugates (ADCs) using ...

Kashiv Biosciences, LLC, a global leader in biopharmaceutical innovation, today announced that their abatacept biosimilar ...

Researchers designed oligopeptides that could co-assemble with therapeutic cargoes to create nanoparticles that improved the ...

The purpose of this study was to evaluate the pharmacokinetics of intranasal hydromorphone hydrochloride (HCl) in patients with vasomotor rhinitis. Methods: Ten patients completed the randomised ...

Vigil Neuroscience, Inc., a clinical-stage biotechnology company listed on the Nasdaq under the symbol VIGL, recently unveiled promising results from its Phase 1 clinical trial for the experimental ...

The U.S. Food and Drug Administration (FDA) has accepted for review Biologics License Applications (BLA) for AVT05, ...

In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion ...

Novo Nordisk's amycretin trial results highlight significant weight loss in adults with obesity, with further clinical ...

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) stock has touched a 52-week low, dropping to $0.72, as the company faces a ...